邱钧, 金俊余, 孙建国, 等. 实时定量PCR检测miR-373*、miR-200c在乳腺癌干细胞中的表达及其靶基因预测[J]. 第三军医大学学报, 2011, 33(10): 984-987. [2]Yu J, Ohuchida K, Mizumoto K, et al. MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation[J]. Mol Cancer, 2010, 9: 169. [3]Vrba L, Jensen T J, Garbe J C, et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells[J]. PLoS One, 2010, 5(1): e8697. [4]Ceppi P, Mudduluru G, Kumarswamy R, et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer[J]. Mol Cancer Res, 2010, 8(9):？ 1207-1216. [5]Tanic M, Yanowsky K, Rodriguez-Antona C, et al. Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene[J]. PloS One, 2012, 7(6): e38847. [6]Kopp F, Wagner E, Roidl A. The proto-oncogene KRAS is targeted by miR-200c[J]. Oncotarget, 2014, 5(1):？ 185-195. [7]Liu Y, Zhang M, Qian J, et al. miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells[J]. DNA Cell Biol, 2015, 34(6):？ 429-436. [8]Hara T, Jones M F, Subramanian M, et al. Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells[J]. Oncotarget, 2014, 5(17):？ 7635-7650. [9]Okudela K, Suzuki T, Umeda S, et al. A comprehensive search for microRNAs with expression profiles modulated by oncogenic KRAS:？ potential involvement of miR-31 in lung carcinogenesis[J]. Oncol Rep, 2014, 32(4):？ 1374-1384. [10]Mahdavinezhad A, Mousavi-Bahar S H, Poorolajal J, et al. Evaluation of miR-141, miR-200c, miR-30b Expression and Clinicopathological Features of Bladder Cancer[J]. Int J Mol Cell Med, 2015, 4(1): 32-39. [11]Liu X G, Zhu W Y, Huang Y Y, et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer[J]. Med Oncol, 2012, 29(2): 618-626. [12]Ouerhani S, Bougatef K, Soltani I, et al. The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer[J]. Mol Biol Rep, 2013, 40(6):？ 4109-4114.
